In tumors derived from the murine KLN205 cancer cells, sitravatinib significantly reduced the proportion of PD-L1-expressing-MDSCs and tumor-associated macrophages among CD11b+ cells and increased T-cell infiltration (CD3+, CD4+ CD8+, Ki67+ PD-1+ CTLA-4+). Here, PDCD1 is linked to cancer.